Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + mirtazapine
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of duloxetine (an SNRI) and mirtazapine (a NaSSA) used primarily for treatment-resistant depression. This combination works through complementary mechanisms - duloxetine inhibits serotonin and norepinephrine reuptake while mirtazapine acts as an antagonist at presynaptic alpha-2 adrenergic receptors and certain serotonin receptors. The combination may provide enhanced antidepressant effects compared to monotherapy, particularly in treatment-resistant cases.
- Other names
- Limerick rocket fuel
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)ADRA2A (α2A)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)5-HT2 (5-HT2 receptor family)
Beyond the preview
Go deeper on duloxetine + mirtazapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duloxetine + mirtazapine.